The SARS-CoV-2 pandemic has worsened since publication of our initial recommendations for the management of autoimmune bullous diseases (AIBDs) during the COVID-19 outbreak in April 2020.1 Based on the rapidly emerging increase of knowledge, this consensus of an expanded panel of international AIBD experts perceives as prosecution of the existing recommendations to promote optimal care during the pandemic.
Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID‐19 pandemic